BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Abolish Health Cess Ad Valorem on medical devices: Edwards Lifesciences

01 February 2022 | News

Arnab Basumallik, Director â?? Government Affairs, Edwards Lifesciences



"On Government Public procurement side, we see adoption of Transparent Quality criteria, 75 % of mandatory payments of running bills, usage of surety bonds instead of bank guarantee and usage of e-bills. We Sincerely hope the same policy will be extended to procurement of medical technologies as well – which will lead to much needed value- based- procurement in health care – which will further improve patient outcome and help achieving ease of doing business. Moreover, we see efforts for adoption of Circular Economy with active public policies on regulation – may help Tier 2 and Tier 3 citi's aspirational hospitals to get refurbished medical devices.

On the direct taxation and duties, we see that while the duties and cess is reduced for some devices, but the same is enhanced for Dialyzers and X-rays and hearing devices. We request the same can reconsidered, considering patient affordability. We also look forward for the abolishing of Health Cess Ad Valorem on Medical Devices for all devices for increasing affordability especially when 86 % devices are imported."